Trastuzumab Deruxtecan for Patients with HER2+ Breast Cancer (DESTINY-Breast12)

What is the Purpose of this Study?

If you agree to take part in this study, you will:
- Get the study drug as an infusion (through IV) every 3 weeks
- Have physical exams and blood draws
- Have heart scans (ECG)
- Have imaging scans (MRI or CT)
What is the Condition Being Studied?
HER2+ Breast Cancer

Who Can Participate in this Study?

Adults ages 18+ who:

- Have HER2+ metastatic breast cancer that is unable to be removed with surgery

- Have previously treated stable or progressing brain metastasis

- Have never been treated with tucatinib

- Are taking 2mg or less of daily dexamethasone

- Have had no more than 2 lines of treatment for brain metastasis

- Are not pregnant

For more information about who can be in this study, please contact the study team at 919-684-5301.

Age Group
Adults
Participating Institutions

What is Involved?

We are doing this study to learn more about how trastuzumab deruxtecan (the study drug) might provide a positive benefit to people with metastatic breast cancer.

Study Details

Full Title
An Open-Label, Multinational, Multicenter, Phase 3b/4 Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously-Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)
Principal Investigator

Contacts
Tisch Brain Tumor Center DCI Clinical Research Team
Protocol Number
IRB:
PRO00108268

NCT:
NCT04739761
ClinicalTrials.gov
View on ClinicalTrials.gov